# Feeling better and changing cartilage aren't the same result *Soreness and Joint Changes — regenerative therapy peoria* > A regenerative therapy Peoria guide to soreness, movement, X-rays, and why feeling better doesn't prove cartilage changed. This page explains why soreness and an X-ray don't always tell the same thing. Relief can come while the X-ray stays unchanged, and cartilage may change while aching remains. Your comfort and daily movement still matter when judging care. ## An X-ray shows wear but can't show how your day went An X-ray may show thin cartilage, bone changes, or a narrowed joint. It can't show whether you slept well or walked to the mailbox. Similar X-rays don't always bring similar soreness. Swelling, muscle strength, old injuries, sleep, and daily work all make a difference. Tell the examiner which ordinary jobs have become hard, not only where you hurt. Dressing, stairs, walking time, and sleep add useful details to the X-ray. ## Less soreness doesn't prove new cartilage grew Platelet-rich plasma, or PRP, uses blood that's spun so one portion holds more platelets. The clinic then places that saved portion inside the aching joint. Some studies found less soreness or easier movement, while another found no more relief than saline. Saline is salt water placed into the joint so researchers can make a fair comparison. Joint regeneration means new cartilage or other joint tissue replacing damaged tissue. A good week doesn't prove that happened, even when the relief is welcome. ## Ordinary tasks show whether care earned its cost Pick a few useful jobs and note how they go from week to week. You might watch sleep, stairs, the grocery aisle, or rising from a chair. A short record beats trying to recall one good or bad afternoon. It'll help you see whether relief lasted and whether further care seems worth paying for. Bring the notes if you arrange an exam. QC Kinetix offers regenerative treatments in which its medical providers take material from blood or bone marrow, prepare it at the clinic, and set it inside the sore joint without surgery to aim for less soreness and easier movement. ## Sources 1. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative. Bennell KL, et al. — [Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/34812863/). *JAMA*, 2021. DOI: 10.1001/jama.2021.19415. 2. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred. Mautner K, et al. — [Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.](https://pubmed.ncbi.nlm.nih.gov/37919438/). *Nature medicine*, 2023. DOI: 10.1038/s41591-023-02632-w. 3. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit. Awad G, et al. — [Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.](https://pubmed.ncbi.nlm.nih.gov/41863718/). *Clinical rheumatology*, 2026. DOI: 10.1007/s10067-026-08042-w. 4. FORWARD, the longest disease-modifying osteoarthritis drug trial reported to date, gave intra-articular sprifermin (a recombinant FGF-18) or placebo to knee OA patients and followed 378 of them for 5 years. Sprifermin produced a significant, sustained dose-response INCREASE in total femorotibial cartilage thickness versus placebo - and WOMAC pain improved about 50% from baseline in ALL groups, including placebo. It is the cleanest demonstration in the literature that adding measurable cartilage and relieving pain are two different results, and that one does not deliver the other. Eckstein F, et al. — [Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.](https://pubmed.ncbi.nlm.nih.gov/33962962/). *Annals of the rheumatic diseases*, 2021. DOI: 10.1136/annrheumdis-2020-219181. 5. A GRADE-rated systematic review and meta-analysis of 16 randomized trials (807 participants) found that MSC therapy for chronic knee OA pain PROBABLY RESULTS IN LITTLE TO NO DIFFERENCE in pain relief at 3-6 months (WMD -0.74 cm on a 10 cm VAS against a minimally important difference of 1.5 cm) or physical functioning (WMD 2.23 on the SF-36 100-point subscale against a 10-point MID), both moderate certainty; at 12 months pain was again probably little-to-no-different (WMD -0.73 cm). The measured effect is real but sits BELOW the threshold at which a patient would notice it. Sadeghirad B, et al. — [Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials.](https://pubmed.ncbi.nlm.nih.gov/38777213/). *Osteoarthritis and cartilage*, 2024. DOI: 10.1016/j.joca.2024.04.021. ## A few written details can make the visit useful Write down which motion hurts, how long the soreness lasts, and what has helped. Bring any X-ray report and your medicines, since those details can save time. The Peoria office is at 13128 N. 94th Drive, Suite 205, near Thunderbird Road. Call the Phoenix-area team at (602) 837-PAIN to ask about a consultation and available options. Book an appointment: --- Straight answers for a sore joint. Plain Peoria help with joint soreness, things to try yourself, times to seek urgent care, and local choices. Plain Peoria guidance on joint soreness, home care, warning signs, and treatment choices. This site is operated by the owners of the QC Kinetix Phoenix-area clinics, including the Peoria location recommended here, and those owners may benefit when a reader books. © 2026 Peoria Joint Field Guide. General health education, not personal medical advice; urgent warning signs require prompt medical care.